Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

In an Imperfect World: Strategies for Psychiatric Clinical Trials


Studies involving psychiatry drugs may be uniquely challenging.

Tweetables from this article:

Tweet: Not all symptomatic improvement in mental disorders can necessarily be tied to the product under study. http://ctt.ec/lf2Zz+ Not all symptomatic improvement in mental disorders can necessarily be tied to the product under study.

Share this!

September 16, 2016 | by Megan Sims

In a perfect world, clinical drug trials draw conclusive results from objective observations. But we don’t live in that world, and we doubt you do, either.

Studies involving psychiatry drugs may be uniquely challenging. Ensuring that trial data accurately captures a compound’s safety and efficacy potential requires that you account for challenges inherent in working with a mentally ill population. Observing changes in the disease under study is partly a subjective process, and that creates risk of undue influence that the patient and/or investigator may not recognize.

To further complicate things, not all symptomatic improvement in mental disorders can necessarily be tied to the product under study. Some changes may result from unrelated factors whose therapeutic effect erodes the efficacy signal of a potential treatment.

On Tuesday, September 20, join two experts from Premier Research for a revealing look at these challenges. Krista Armstrong, Vice President of Strategic Development, and Susan Kozauer, Senior Medical Director, will present Conclusive Results: Strategies for Collecting Quality Data in Psychiatric Clinical Trials. The hour-long session, beginning at 11 a.m. Eastern time, will explore a range of factors that — if identified and mitigated early in the development process — can maximize the potential for conclusive study results. Look for a particular focus on:

  • Study design considerations
  • Site factors
  • Subject selection and eligibility
  • Data surveillance

The neuroscience experts at Premier Research have performed more than 150 neuroscience studies in just the past five years, their work touching more than 27,000 patients afflicted with all major central nervous system disorders. Register today for what is sure to be an informative presentation.

Keywords: Premier Research, Psychiatry, Clinical Trials



        Share this with your colleagues!

        Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

        March 22, 2017 - In response to the growing threat posed by drug counterfeiting, international regulators have begun implementing guidelines aimed at increasing control over the pharmaceutical supply chain. Will these efforts be enough?

        The Future of Real-World Evidence

        March 14, 2017 - Life Sciences companies are performing advanced analytics, including cohort and predictive analytics, on top of these Real-World Evidence (RWE) data sources to understand the performance of their drugs and devices when used by actual, non-clinical trials patients.

        Pharmaceutical Industry Cannibalization: The Launch of Authorized Generics After the Loss of Market Exclusivity

        March 7, 2017 - Once a drug begins to reach the end of its patent period, it’s vulnerable to being scooped up by generic drugmakers who seek to develop a copycat version of the medication. Authorized generics are identical to the company’s branded product in terms of both active and inactive excipient ingredients; the only thing missing is the brand name and packaging that comes along with it.


        Top Ten Webinar Production Tips of 2016


        Strategies for Deploying Innovative Solutions for Perimeter Security

        Natural History vs. Registry Studies in Rare Disease

        The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review

        Combination Product Regulatory Requirement Complexities and the Impact of the 21st Century Cures Act

        Copyright © 2016-2017 Honeycomb Worldwide Inc.